Journament

Keyword Connections - pd-l1 Keywords

Connection Type	Connection
Journals	PloS one international immunopharmacology Frontiers in immunology Virology Aging the oncologist oncoimmunology aorta (stamford, conn) journal of autoimmunity immunity
Research Groups	No Research Group Connected
Bibliographies	[1] The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality. [2] Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition. [3] Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. [4] Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients. [5] MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. [6] NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy. [7] Primary Sarcoma of Descending Aorta. [8] pd-1/pd-l1 blockade: have we found the key to unleash the antitumor immune response? [9] cancer immunotherapies targeting the pd-1 signaling pathway [10] reversing egfr mediated immunoescape by targeted monoclonal antibody therapy [11] prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma [12] advances of pd-1/pd-l1 inhibitors in tumor immunotherapy [13] regulation of pd-l1: emerging routes for targeting tumor immune evasion [14] Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors [15] EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes [16] PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression [17] Targeting Immune Cell Checkpoints during Sepsis [18] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. [19] Reprogramming of radiation-deteriorated TME by liposomal nanomedicine to potentiate radio-immunotherapy. [20] Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab. [21] Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. [22] "Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. [23] Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy [24] Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. [25] PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma [26] Design of PD-L1 inhibitors for lung cancer. [27] Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort [28] Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA. [29] Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines. [30] Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer. [31] Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice [32] Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. [33] MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. [34] Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer Proliferation [35] NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy. [36] pd-1/pd-l1 blockade: have we found the key to unleash the antitumor immune response? [37] durvalumab: an investigational anti-pd-l1 monoclonal antibody for the treatment of urothelial carcinoma [38] anti pd-l1 durvalumab combined with cetuximab and radiotherapy in locally advanced squamous cell carcinoma of the head and neck: a phase i/ii study (ducro) [39] association of pd-l1 and hif-1α coexpression with poor prognosis in hepatocellular carcinoma [40] clec1b expression and pd-l1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage [41] enhancement of psma-directed car adoptive immunotherapy by pd-1/pd-l1 blockade [42] advances of pd-1/pd-l1 inhibitors in tumor immunotherapy [43] regulation of pd-l1: emerging routes for targeting tumor immune evasion [44] PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations [45] Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors [46] EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes [47] PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression [48] Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2 [49] Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer. [50] Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination [51] Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination [52] Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.